We are acting with flexibility, the experience of more than 120 clinical trials and open communication with you in a joint team to ensure your milestones by managing:

  • Project
    planning

    Compilation of project management plan and definition of key parameters (milestones, budgets, resources, logistics, project tools)

  • Project
    performance

    Budgeting and cost management of development projects. Resources management and co-ordination of all third party providers contracted

  • Quality
    assurance

    Quality is the backbone of a clinical trial. Our systematic approach ensures high-quality data and is the basis of our daily business.

  • Risk
    management

    A proper risk assessment is used to plan the details of trial management and the approach to and extent of monitoring and controlling the trial

Sacura‘s employees covered key functions in more than 120 clinical trials open third tab

Studies overview

Our Team worked on following international Phase II - IV studies open third tab

  • Antiinfective drugs
    Quinolones (gyrase inhibitors)
    Cephalosporins
    Macrolides
    Skin and subcutaneous tissue disorders
    Onychomycosis
    Brittle nail syndrome
    Psoriasis
    Respiratory disorders
    Acute asthma
    COPD
    Exacerbation of chronic bronchitis
    and acute bronchitis (Paediatrics)
    Pneumonia
    Maxillary sinusitis
    Infections
    Influenza
    H5N1
    HIV
    Sepsis
    Blood and lymphatic system disorders
    Tonsillitis
    Ear and labyrinth disorders
    Otitis media
    Acute tinnitus
    Endocrine,Metabolic and Nutrition disorders
    Diabetes mellitus type I / II
    Impaired glucose tolerance
    Hypercholesterolemia
    Partial androgen deficiency of
    aging males (PADAM)
    Dyslipidaemia (primary/mixed) -
    Frederickson Types IIa & IIb
    Low HDLc
  • Gastrointestinal disorders
    Irritable bowel disease
    Gastro esophageal reflux
    disease (GERD)
    Mucositis in children and adults
    undergoing stem cell transplantation
    Cardio and cardiovascular diseases
    Coronary heart disease
    Hypertension
    Renal and urinary tract diseases
    Pyelonephritis
    Urinary tract infection
    Stress urinary incontinence
    Mixed urinary incontinence
    Overactive bladder
    Renal impairment
    Reproductive system and breast disorders
    Dysfunctional uterine bleeding
    Endometriosis
    Benign prostate hyperplasia
    Erectile dysfunction
    Premature ejaculation
    Musculoskeletal and bone diseases
    Rheumatoid arthritis
    Osteoarthritis of the knee
    Postmenopausal osteoporosis
    Nerve system disorders
    Vascular dementia
    Alzheimer's disease
    Post herpetic neuralgia
    Painful diabetic neuropathia
    Restless legs syndrome
    Chronic non-malignant pain
    Multiple sclerosis
    Spinal cord injury
  • Psychiatric disorders
    Schizophrenia
    Tumor diseases
    Breast cancer
    AML
    CLL
    SCLC
    Osteosarcoma
    Metastatic epithelial tumor cells
    diagnostic in mamma and
    colon carcinoma patients
    Congenital, familial and genetic disorders
    Amyloidosis (Familial amyloid polyneuropathia, FAP)
    Hereditary angioedema
    Immune system disorders
    Neutropenia
    Pediatric diseases
    Neonatology
    Other
    Parenteral nutrition
    Vitamin C
    Radiographic contrast media
    Medical devices

Our regions of activity open third tab

Regions overview
  • Argentina
    Austria
    Belgium
    Canada
  • Denmark
    Finland
    France
    Germany
  • Great Britain
    Hungary
    Ireland
    Israel
  • Italy
    Lithuania
    Netherlands
    Norway
  • Portugal
    Poland
    Spain
    Suisse
  • Sweden
    Ukraine
    United States
    Russia

Long-term and orphan drug experience with specific focus of authorities on control of these studies enables us to implement the current thinking of the FDA and EMA in our daily activities.open fourth tab

  • Inspections-related Track Record of our team:

    FDA Site and TMF inspection, Germany/USA, April/June 2012
    MoH GCP inspection, Argentina, September 2011
    Mock inspection, Germany, December 2011
    Mock inspection, Germany/USA, May 2011
    Mock inspection, Germany, November 2010
    FDA inspection, Austria, March 2008